December 2016
-
Verona Pharma says that the FDA’s comments in response to the data from a Phase 2 study of the company’s RPL554 nebulized ensifentrine for the treatment of COPD support moving ahead with a Phase 3… Read more . . .
-
Senzer Pharmaceuticals has announced the launch of a new Critical Care Division for development of two inhaled anti-viral drugs for the treatment of COVID-19. The company did not specify which drugs it planned to develop… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its Airz-FF glycopyrronium/formoterol/fluticasone propionate triple combination inhaler for the treatment of COPD in India. The company said that “AIRZ-FF has been exclusively studied in the Indian population and introduced to… Read more . . .
-
Oyster Point Pharma has announced that the Phase 3 ONSET-2 trial of the company’s OC-01 varenicline nasal spray for the treatment of dry eye disease met its primary endpoint, demonstrating significant improvement in tear film… Read more . . .
-
A consortium called Fraunhofer International Consortium for Anti-Infective Research (iCAIR) — composed of researchers from Fraunhofer ITEM, Griffith University, Hannover Medical School, and Twincore — has announced that it has initiated a project to develop… Read more . . .
-
Spray characterization specialist Proveris Scientific has announced that it is now offering contract testing services for OINDP regulatory submissions, release testing and stability studies, as well as for development projects. The company received ISO 9001:2015… Read more . . .
-
Pulmotect said that it plans to initiate two Phase 2 trials of its PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19 within a week after getting the go-ahead from the FDA. In… Read more . . .
-
The FDA has approved an IND for a Phase 2 study of GeneOne Life Science’s GLS-1200 nasal spray for the prevention of COVID-19, the company said. According to GeneOne, GLS-1200 stimulates nasal production of nitric… Read more . . .
-
Impel NeuroPharma has announced the resignation of Jon Congleton as President and CEO; Adrian Adams, who was appointed as Impel’s Chairman of the Board of Directors in January 2020, will now add the CEO role. Adams has… Read more . . .
-
DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo’s multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK